CCDC71L: A Potential Drug Target and Biomarker (G168455)

Target Name: CCDC71L

NCBI ID: G168455

CCDC71L

CCDC71L: A Potential Drug Target and Biomarker

The cancer drug market is one of the fastest-growing sectors in the pharmaceutical industry. Cancer is a leading cause of death worldwide, and there is a significant demand for new treatments to address the diverse range of cancer types. One promising candidate for cancer treatment is CCDC71L, a protein that has been identified as a potential drug target and biomarker.

CCDC71L is a cell surface glycoprotein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. It is a heat-labile protein with a molecular weight of approximately 180 kDa. CCDC71L is involved in various physiological processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in cancer progression and metastasis.

The potential drug target for CCDC71L is its role in cell adhesion and migration. Cancer cells have a unique ability to migrate and invade into surrounding tissues, which allows them to escape from the immune system and establish new tumors. CCDC71L is involved in these processes by helping cells stick together and form tight junctions, which are essential for the formation of tissues and organs.

In addition to its role in cell adhesion and migration, CCDC71L has also been shown to contribute to the development and progression of various cancers. For example, studies have shown that high levels of CCDC71L are associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer. Similarly, CCDC71L has been shown to be upregulated in various types of cancer, including lung, breast, and colorectal cancer.

As a potential drug target, CCDC71L offers several advantages as a therapeutic target. First, it is relatively easy to target, as it is a protein that is expressed in various tissues and can be easily isolated from cells. Second, CCDC71L is involved in multiple physiological processes, which makes it a promising target for drugs that can affect a wide range of cellular processes. Finally, CCDC71L has been shown to play a role in cancer progression and metastasis, which makes it an attractive target for drugs that can inhibit its activity.

In addition to its potential as a drug target, CCDC71L has also been identified as a potential biomarker for cancer. The ability of CCDC71L to be expressed in various tissues and organs makes it an attractive candidate for diagnostic tools. For example, CCDC71L has been shown to be expressed in pancreatic cancer cells and has been used as a biomarker to predict the outcome of pancreatic cancer surgery. Similarly, CCDC71L has been shown to be expressed in other types of cancer, including lung, breast, and colorectal cancer.

While the potential of CCDC71L as a drug target and biomarker is an exciting development, there are also challenges that must be addressed. For example, the lack of human studies with CCDC71L makes it difficult to determine its safety and efficacy in humans. Additionally, the ability of CCDC71L to contribute to cancer progression and metastasis means that it will be important to study its effects on cancer cells in the context of a full-length animal model.

In conclusion, CCDC71L is a promising candidate for cancer treatment as a drug target and biomarker. Its role in cell adhesion and migration, as well as its involvement in cancer progression and metastasis, make it an attractive target for drugs that can inhibit its activity. While there are challenges that must be addressed, the potential of CCDC71L makes it an important area of research for the pharmaceutical industry.

Protein Name: Coiled-coil Domain Containing 71 Like

The "CCDC71L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC71L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets